## **RUNX1** inhibits proliferation and induces apoptosis of t(8;21) leukemia cells *via* KLF4-mediated transactivation of P57

Shuang Liu,<sup>1\*</sup> Yanyan Xing,<sup>1\*</sup> Wenting Lu,<sup>1</sup> Shouyun Li,<sup>1</sup> Zheng Tian,<sup>1</sup> Haiyan Xing,<sup>1</sup> Kejing Tang,<sup>1</sup> Yingxi Xu,<sup>1</sup> Qing Rao,<sup>1</sup> Min Wang<sup>1</sup> and Jianxiang Wang<sup>1,2</sup>

\*These authors contributed equally to this work.

<sup>1</sup>State Key Laboratory of Experimental Hematology and <sup>2</sup>National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, P.R. China

©2019 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2018.192773

Received: March 5, 2018. Accepted: February 20, 2019. Pre-published: February 21, 2019. Correspondence: *JIANXIANG WANG* - wangjx@ihcams.ac.cn *MIN WANG* - wangjxm@ihcams.ac.cn

## **Supplementary Data**

## **Supplementary Materials**

#### **Plasmids construction**

KLF4 and P57 promoter fragments containing putative RUNX1 and KLF4 binding sites were cloned from human genomic DNA by PCR with the primers listed in Supplementary Table. The amplified fragments were then inserted into the pGL3-Basic vector (Promega, USA) and named as pGL3-KLF4 and pGL3-P57, respectively.

KLF4 target genes reporter plasmid (KLF4-Reporter) was constructed by inserting four tandem-linked response elements of KLF4 (AGGGTGTGGCC) into the pGL3-Basic vector through KpnI and Bgl II restriction enzyme digestion sites.

The pCMV5-RUNX1, pCMV5-RUNX1-ETO and pCMV5-KLF4 plasmids were preserved by our laboratory. Full-length and different truncation mutants of RUNX1 and RUNX1-ETO were cloned from pCMV5-RUNX1 and pCMV5-RUNX1-ETO plasmids and inserted into the pCMV5-vector with the primers listed in Supplementary Table. Lentiviral vectors used in this study were constructed by cloning the open reading frame of RUNX1, KLF4 and P57 respectively into the pCDH-EF1-MCS-T2AcopGFP vector (System Biosciences, Mountain View, CA) with primers listed in Supplementary Table.

# Lentiviral preparation and transduction of Kasumi-1 cells and HL-60 cells

Lentiviral vectors were co-transfected with packaging vectors psPAX2 and pMD2.G into HEK293T cells using polyethylenimine (PEI) (Polysciences, Warrington,

PA, USA) to produce lentivirus. At 24h and 48h after transfection, viral supernatants were collected and concentrated to 100-fold by ultracentrifugation after pelleting cell debris. Then Kasumi-1 cells and HL-60 cells were transduced overnight with concentrated virus in the presence of polybrene (Sigma, USA) at a final concentration of 8  $\mu$ g/mL.

#### **RNA isolation and real-time quantitative PCR (qRT-PCR)**

RNA was extracted using RNAiso Plus (Takara, Japan) and reverse-transcribed into cDNA using M-MLV Reverse Transcriptase (Life technologies, USA). qRT-PCR analysis was performed on a 7500 Real-Time PCR system (Applied Biosystems, USA) with SYBR Green PCR kit (Takara, Japan) following the manufacturer's instructions. Primers for *RUNX1*, *KLF4* and *P57* were listed in Supplementary Table.

#### Western blot assay

Western blot assays were performed as previously described <sup>1</sup> with the following primary antibodies: RUNX1 (Abcam, ab54869, USA); KLF4 (CST, #12173, USA); KLF4 (Abcam, ab151733, USA), P57 (CST, #2557, USA); ETO (Abcam, ab124269, USA); FLAG (Sigma, F3165, USA); MYC (CST, #2276, USA); ACTIN (Sigma, A1978, USA) and H3 (Abcam, ab61251, USA).

#### MTS assay

GFP<sup>+</sup> Kasumi-1 cells and HL-60 cells were sorted by flow cytometry at 72h after lentivirus infection. Then cell proliferation ability was measured by MTS assay as previously described <sup>1</sup>.

#### Cell cycle analysis

After 72h of lentivirus infection, GFP<sup>+</sup> cells were sorted by flow cytometry and cell cycle analyses were performed as previously described <sup>1</sup>. Cell cycle distribution was calculated by ModFit software.

# Apoptosis assessment by Annexin V staining and morphological analysis

At 48h and 72h after lentivirus infection,  $1 \times 10^{6}$  cells were collected, washed with  $1 \times$ AnnexinV binding buffer twice and stained with Annexin V-Alexa Fluor 647-A and PI (Biolegend, USA) according to the manufacturer's instructions. Apoptosis assay was performed with flow cytometry (Canto II, BD, USA) and Annexin V<sup>+</sup> cells in GFP<sup>+</sup> population were calculated. For morphological analysis, cytospins of GFP<sup>+</sup> cells were prepared at different time after flow sorting and stained with Wright-Giemsa solution. Then the morphological images were captured using a Nikon Eclipse 50i microscope (Nikon Inc., Melville, NY, USA).

#### **Cell differentiation analysis**

At 48h and 72h after lentivirus infection,  $1 \times 10^6$  cells were collected and stained with the following antibodies: APC-CD11b (Biolegend, USA), PE-CD15 (Biolegend, USA) or the relative isotype controls. Then the percentage of CD11b<sup>+</sup> and CD15<sup>+</sup> cells in GFP<sup>+</sup> population were determined by flow cytometry (Canto II, BD, USA).

#### References

1. Liu S, Lu W, Li S, Li S, Liu J, Xing Y, et al. Identification of JL1037 as a novel,

specific, reversible lysine-specific demethylase 1 inhibitor that induce apoptosis and

autophagy of AML cells. Oncotarget. 2017 Mar 29; 8(19):31901-31914.

### **Supplementary Table**

#### Lists of primers used in this study

#### Primer name

KLF4\_promoter\_BgI II\_fwd KLF4\_promoter\_BgI II\_rev P57\_promoter\_Kpn I\_fwd P57\_promoter\_BgI II\_rev RHD\_EcoR I\_fwd

RHD\_BamH I\_rev RUNX1 full-length\_BgI II\_fwd RUNX1 full-length\_Cla I\_rev RUNX1△RHD\_N terminal\_BgI II\_fwd RUNX1△RHD\_N terminal\_rev

RUNX1△RHD\_C terminal\_fwd

RUNX1△RHD\_C terminal\_Cla I\_rev RUNX1△RHD\_overlap\_Bgl II\_fwd RUNX1△RHD\_overlap\_Cla I\_rev RUNX1-ETO full-length\_Kpn I\_fwd RUNX1-ETO full-length\_Xba I\_rev RUNX1-ETO△RHD\_N terminal\_Kpn I\_fwd RUNX1-ETO△RHD\_N terminal\_rev

RUNX1-ETO ARHD\_C terminal\_fwd

RUNX1-ETO $\triangle$ RHD\_C terminal\_Xba I\_rev RUNX1-ETO $\triangle$ RHD\_overlap\_Kpn I\_fwd RUNX1-ETO $\triangle$ RHD\_overlap\_Xba I\_rev KLF4\_EcoR I\_fwd KLF4\_BamH I\_rev RUNX1\_EcoR I\_fwd RUNX1\_Not I\_rev KLF4\_EcoR I\_fwd

KLF4\_BamH I\_rev P57\_EcoR I\_fwd P57\_BamH I\_rev RUNX1\_fwd RUNX1\_rev KI F4 fwd KLF4\_rev P57\_fwd P57 rev GAPDH fwd GAPDH\_rev R1 fwd R1\_rev R2 fwd R2\_rev R3\_fwd R3\_rev R4 fwd R4\_rev R5\_fwd R5 rev R6\_fwd

R6\_rev

R7 fwd

R7\_rev

Sequence 5'-3' GGAAGATCTGTGACATAATAATGGTGGCT GGAAGATCTTGGGCCGGGCCGTGACGC CGGGGTACCTTACCCAGTACAACAGCTT GGAAGATCTAGAGGACAGCGAGAAGAA CCGGAATTCGCCACCATGGACCGCAGCATGGTGGA GGTGC CGCGGATCCTTACAGATCCTCTTCTGAGATGAGTTT TTGTTCGTTTCTGCCGATGTCTTCG GGAAGATCTGCCACCATGGCTTCAGACAGCATA CCATCGATTTACAGATCCTCTTCTGAGATGAGTTTTT GTTCGTAGGGCCTCCACACGGCCT GGAAGATCTGCCACCATGGCTTCAGACAGCATA GGGCTTGGTCTGATCATCTAGGCCGCTCCTCAGCTT GCCG CGGCAAGCTGAGGAGCGGCCTAGATGATCAGACCA AGCCC CCATCGATTTACAGATCCTCTTCTGAGATGAGTTTTT GTTCGTAGGGCCTCCACACGGCCT GGAAGATCTGCCACCATGGCTTCAGACAGCATA CCATCGATTTACAGATCCTCTTCTGAGATGAGTTTTT GTTCGTAGGGCCTCCACACGGCCT CGGGGTACCGCCACCATGCGTATCCCCCGTAGATGC TGCTCTAGATTACAGATCCTCTTCTGAGATGAGTTTT TGTTCGCGAGGGGTTGTCTCTATGG CGGGGTACCGCCACCATGCGTATCCCCGTAGATGC GAGTGCTTCTCAGTACGATTGCCGCTCCTCAGCTTG CCGG CCGGCAAGCTGAGGAGCGGCAATCGTACTGAGAAG CACTC TGCTCTAGATTACAGATCCTCTTCTGAGATGAGTTTT TGTTCGCGAGGGGTTGTCTCTATGG CGGGGTACCGCCACCATGCGTATCCCCGTAGATGC TGCTCTAGATTACAGATCCTCTTCTGAGATGAGTTTT TGTTCGCGAGGGGTTGTCTCTATGG CCGGAATTCGCCACCATGAGGCAGCCACCTGGCGA CGCGGATCCTTACTTATCGTCGTCATCCTTGTAATCA AAATGCCTCTTCATGTG CCGGAATTCGCCACCATGGCTTCAGACAGCATATT ATAAGAATGCGGCCGCCAGATCCTCTTCTGAGATGA GTTTT CCGGAATTCGCCACCATGAGGCAGCCACCT CGCGGATCCCTTATCGTCGTCATCCTTGTAATCAAA ATGCCTCTTCATG CCGGAATTCGCCACCATGTCCGACGCGTCCCTCC CGCGGATCCCAGATCCTCTTCTGAGATGAGTTTTTG TTCCCGCAGCCTCTTGCGCGG ACCGACAGCCCCAACTTCCT GCTTTTCCCTCTTCCACTTC CAAGTCCCGCCGCTCCATTACCAA CCACAGCCGTCCCAGTCACAGTGG CTGACCAGCTGCACTCGGGGGATTTC GCCGCCGGTTGCTGCTACATGA GAAGGTGAAGGTCGGAGTC GAAGATGGTGATGGGATTTC TGGTGGCTTTCCAATTCTTCT AAAGCCAAAGTCCCTCACCC GTGGTGAGTTTCCCATGCAG TGGGGGATGAGAGTGTTTTGG GAAGTCACACTCAAGGGCGT ACCTGTTTGAACCCTGCGAT AAGTGGAAAGGAGAGTGCGT CACGACGCCGGCTAATTTTT TGAGCCCTTTCACTCCCTTTC AGCCTCAAGAGAAGGCCAGA TAATCGCGCTCTTCTCCAGC CCGTACTCACCGCCATTGTC not suitable not suitable

#### Use

construction of pGL3-KLF4 construction of pGL3-KLF4 construction of pGL3-P57 construction of pGL3-P57

construction of pCMV5-RHD-myc

construction of pCMV5-RHD-myc construction of pCMV5-RUNX1-myc construction of pCMV5-RUNX1-myc construction of pCMV5-RUNX1△RHD-myc construction of pCMV5-RUNX1△RHD-myc construction of pCMV5-RUNX1△RHD-myc

construction of pCMV5-RUNX1 $\triangle$ RHD-myc construction of pCMV5-RUNX1 $\triangle$ RHD-myc construction of pCMV5-RUNX1-ETO-myc construction of pCMV5-RUNX1-ETO-myc construction of pCMV5-RUNX1-ETO $\triangle$ RHD-myc construction of pCMV5-RUNX1-ETO $\triangle$ RHD-myc

construction of pCMV5-RUNX1-ETO $\triangle$ RHD-myc

construction of pCMV5-RUNX1-ETO $\triangle$ RHD-myc construction of pCMV5-RUNX1-ETO $\triangle$ RHD-myc construction of pCMV5-RUNX1-ETO $\triangle$ RHD-myc construction of pCMV5-KLF4-flag


construction of pCMV5-KLF4-flag

construction of pCDH-EF1-RUNX1-myc-T2A-copGFP construction of pCDH-EF1-RUNX1-myc-T2A-copGFP construction of pCDH-EF1-KLF4-flag-T2A-copGFP construction of pCDH-EF1-KLF4-flag-T2A-copGFP construction of pCDH-EF1-P57-myc-T2A-copGFP

gRT-PCR gRT-PCR aRT-PCR qRT-PCR qRT-PCR gRT-PCR aRT-PCR qRT-PCR ChIP-PCR ChIP-PCR

ChIP-PCR

## **Supplementary Figure**



### Figure S1 Endogenous interaction between KLF4 and RUNX1/ RUNX1-ETO

(A) KLF4 interacted with RUNX1 in Kasumi-1 and SKNO-1 cells. Endogenous interaction analysis of KLF4 and RUNX1 in Kasumi-1 and SKNO-1 cells with anti-RUNX1 (IP) and anti-KLF4 (IB) antibodies. (B) KLF4 interacted with RUNX1-ETO in Kasumi-1 and SKNO-1 cells. Endogenous interaction analysis of KLF4 and RUNX1-ETO in Kasumi-1 and SKNO-1 cells with anti-ETO (IP) and anti-KLF4 (IB) antibodies.





Figure S2 The biological effects of RUNX1, KLF4 and P57 overexpression on HL-60 cell proliferation, apoptosis and differentiation

(A and B) Overexpression of RUNX1 in HL-60 cells were mediated by a pCDH lentivirus system. At 72h after infection, the infected cells were sorted by flow

cytometry for GFP<sup>+</sup> population and the expression levels of RUNX1 and target genes KLF4 and P57 were measured by qRT-PCR (A) and Western blot (B), respectively. (C) HL-60 cells were infected with pCDH lentivirus overexpressing RUNX1, KLF4 or P57, respectively. At 72h after infection, the infected cells were sorted by flow cytometry for GFP<sup>+</sup> population and the overexpression efficiency was evaluated by Western blot assay. (D) MTS assay was performed to evaluate cell proliferation ability of GFP<sup>+</sup> HL-60 cells overexpressing RUNX1, KLF4 or P57 at 72h after lentivirus infection. (E) Cell cycle distribution of GFP<sup>+</sup> HL-60 cells overexpressing RUNX1, KLF4 or P57 was analyzed by flow cytometry with PI staining at 48h after cell sorting. (F) Cell apoptosis analysis of GFP<sup>+</sup> HL-60 cells overexpressing RUNX1, KLF4 or P57 were performed by the flow cytometry at 48h and 72h after lentivirus infection. (G) Flow cytometry analysis of cell surface markers CD11b of GFP<sup>+</sup> HL-60 cells overexpressing RUNX1, KLF4 or P57 at 48h and 72h after lentivirus infection.



## Figure S3 Representative flow cytometry plots of Kasumi-1 cell differentiation

(A) CD11b representative flow cytometry plots of GFP<sup>+</sup> Kasumi-1 cells overexpressing RUNX1, KLF4 or P57 at 48h and 72h after lentivirus infection. (B) CD15 representative flow cytometry plots of GFP<sup>+</sup> Kasumi-1 cells overexpressing RUNX1, KLF4 or P57 at 48h and 72h after lentivirus infection.